2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 2719

Track Along: Monocytes Follow Fibroblast-like Synoviocyte Network for Movement and Rest within the Synovial Tissue
Abstract Number: 2720

Crucial Role of Nuclear Factor of Activated T Cell 5 (NFAT5), an Osmo-Protective Factor, in Migration and Invasion of Rheumatoid Synoviocytes
Abstract Number: 2721

Elevated Subgingival Levels of Periodontal Pathogens in Rheumatoid Arthritis Patients, Particularly Leptotrichia species in New-Onset Disease
Abstract Number: 2722

Cyclic Phosphatidic Acid (CPA) Suppresses Expression of Cartilage Degrading Enzymes Such As MMP-3, MMP-13 and Adamts-4 in Inflammatory Synovial Fibroblasts and Articular Chondrocytes Induced By IL-1 Beta and/or TNF ALFA
Abstract Number: 2723

Basal STAT5 Signaling Is Elevated in Multiple Peripheral Blood Cell Subsets in Rheumatoid Arthritis and Is Markedly Downregulated By IFN-Î³ in T Lymphocytes
Abstract Number: 2724

Methotrexate Treatment Could Modulate the Abnormal CD4+T Lymphocyte Subset Distribution in NaÏve Rheumatoid Arthritis Patients
Abstract Number: 2725

Secular Trends in Use of Disease Modifying Anti-Rheumatic Drugs for the Treatment of Rheumatoid Arthritis in the United States
Abstract Number: 2726

The Effect of Prior Disease Duration and Prior DMARD Use on Treatment Outcomes in Patients with Early or Established Rheumatoid Arthritis
Abstract Number: 2727

BI 695501, a Proposed Biosimilar for Adalimumab, Shows Bioequivalence to Adalimumab Reference Products in a Randomized, Double-Blind Phase I Trial in Healthy Subjects
Abstract Number: 2728

Baseline Characteristics and Changes in Disease Activity at 12 Months in Patients Treated with Abatacept Versus Other Biologic Disease-Modifying Antirheumatic Drugs in Clinical Practice Setting
Abstract Number: 2729

Clinical and Radiographic Outcome of Iguratimod for Rheumatoid Arthritis
Abstract Number: 2730

Patient-Reported Outcomes from a Phase 3 Study of Baricitinib in Patients with Rheumatoid Arthritis with Inadequate Response to Conventional Synthetic Disease-Modifying Antirheumatic Drugs
Abstract Number: 2731

Persistency of Tocilizumab As Monotherapy or Combination Therapy in Patients with Rheumatoid Arthritis–Real-World Analyses from the US Corrona Registry
Abstract Number: 2732

The Effect of Adrenocorticotropin Gel (HP Acthar Gel) in Combination with MTX in Newly Diagnosed RA Patients from a Clinical and Structural Perspective
Abstract Number: 2733

Effect of Abatacept on Telomerase Activity of Lymphocytes of Patients with Rheumatoid Arthritis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].